CRISPR Therapeutics AG (CRSP)

Market Cap	5.26B +56.6%
Revenue (ttm)	3.51M -90.6%
Net Income	-581.60M
EPS	-6.47
Shares Out	95.99M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,841,542
Open	51.09
Previous Close	51.22
Day's Range	51.05 - 55.09
52-Week Range	33.03 - 78.48
Beta	1.79
Analysts	Buy
Price Target	70.29 (+28.2%)
Earnings Date	May 5, 2026

About CRSP

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company’s CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as deve...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 19, 2016
• Employees: 393
• Stock Exchange: NASDAQ
• Ticker Symbol: CRSP
• Website: https://www.crisprtx.com

Financial Performance

In 2025, CRISPR Therapeutics AG's revenue was $3.51 million, a decrease of -90.59% compared to the previous year's $37.31 million. Losses were -$581.60 million, 58.8% more than in 2024.

Analyst Summary

According to 17 analysts, the average rating for CRSP stock is "Buy." The 12-month stock price target is $70.29, which is an increase of 28.20% from the latest price.

Price Target

$70.29

(28.20% upside)

Analyst Consensus: Buy